Spero Therapeutics Hits New 52-Week Low at $1.51 Amid Market Turmoil

Spero Therapeutics, Inc., a microcap player in the Pharmaceuticals & Biotechnology sector, has recently reached a new 52-week low of USD 1.51 on July 17, 2026. This marks a significant decline from its 52-week high of USD 3.08, reflecting the stock's volatility over the past year. Despite this downturn, Spero Therapeutics has shown a one-year performance of 10.49%, which is notably lower than the S&P 500's performance of 18.43%. The company currently holds a market capitalization of USD 135 million and maintains a price-to-earnings (P/E) ratio of 14.00. Spero Therapeutics does not offer a dividend, and its debt-to-equity ratio stands at -0.65, indicating a unique financial structure. The return on equity is reported at 15.96%, and the price-to-book ratio is 2.29. These metrics provide insight into the company's financial health and market position within the competitive landscape of the biotechnology industry.